
The pharmaceutical flagship Novo Nordisk has rarely been creating as much buzz as it is at the moment. The stock market is alive with enthusiasm, and it is mainly the candidate drug against obesity that is the talk of the town.
The Novo-share has gone up about 25 % since the turn of the year, and Danish newspaper Berlingske reveals that only 1 out of 23 Novo-analysts recommend to sell. 11 say buy and 11 say hold.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app